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Summary 
The immunodominant CD4 T cell epitope of the bacteriophage k cI repressor protein in several 
inbred mouse strains can be represented by a peptide encompassing amino acids 12-26.  Here, 
we show that this peptide, and a variety of its sequence variants,  can induce immediate-type 
hypersensitivity in mice. 12-26 variants that differ by as little as single amino acid residues deviate 
greatly in their ability to induce hypersensitivity. Further, differences in major histocompatibility 
complex class II alleles appear to be as influential as changes in peptide structure in determining 
whether hypersensitivity is developed. The ability of a given peptide-class II combination to 
induce hypersensitivity correlates with production of peptide-specific antibody, but not with 
ability or inability to induce a T  cell proliferative response. Administration of anti-interleukin 
4 (IL-4) mAb prevents the development of hypersensitivity, and analysis of cytokine production 
by T  cell hybridomas derived from peptide-immunized mice suggests  that  whether  a given 
peptide-class II combination can induce hypersensitivity depends on its ability to induce IL-4 
production. The data demonstrate that changes in the nature of the epitope(s) recognized by 
the CD4 T  cell population can result in qualitative differences in the response elicited in this 
population, ultimately leading to dramatic quantitative and qualitative variations in the effector 
phase of the immune response. 
T 
he ligand for most CD4 TCRs of the od/3 type is a com- 
plex of a class  II MHC  molecule and a peptide sub- 
fragment of a protein antigen. This ligand is created on the 
surface of an APC via internalization of the antigen, its degra- 
dation to peptide fragments, and association of some of these 
fragments with class II molecules via agretypic determinants 
on the peptides (1). Linear peptides of 5-20 amino acids bearing 
agretypic and T cell epitypic determinants can substitute for 
intact antigen in in vitro T cell activation assays (2-4). These 
findings have been exploited towards the development of syn- 
thetic peptide vaccines (5, 6), and the design of peptides that 
can block autoimmune T  cell responses in vivo (7,  8). 
Linear synthetic peptides are much simpler in structure 
than the high molecular weight protein antigens normally 
used to elicit immune responses. In addition, synthetic pep- 
tide chemistry allows facile generation of an assortment of 
different mutant forms of any given peptide. Thus, changes 
in putative epitypic and agretypic determinants in a peptide 
can easily be made and assayed for their effect on immunoge- 
nicity in vitro and in vivo. Studies from a number of labora- 
tories have demonstrated the utility of this approach towards 
the elucidation of the structural correlates of T cell immunoge- 
nicity (9-11).  Such studies have shown that changes in the 
primary structure of synthetic peptides often result in altera- 
tions in their immunogenicity that are not easily explained 
by our current understanding of the nature of agretypic and 
epitypic determinants  (12-14). 
While the CD4 T cell immune response to linear synthetic 
peptides is an active area of research, less attention has been 
paid to the B cell (antibody) response to such antigens.  If 
a peptide contains an agretope and B and CD4 T  cell epi- 
topes, it might be expected to elicit a conventional humoral 
response in vivo. Indeed, a variety of short synthetic pep- 
tides have been shown to be capable of inducing vigorous 
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tides should prove useful as chemically  defined model antigens 
for the elucidation of the structural correlates of humoral im- 
munogenicity. In theory, independent changes in the com- 
ponents currently known to be essential  for humoral im- 
munogenicity, namely, B cell and CD4 T cell epitypic as well 
as agretypic determinants, could be made in a given peptide 
and assayed for their influence on the quantitative and qualita- 
tive outcome of the antibody response  to the peptide. 
To initially investigate how changes in the structure of a 
linear synthetic peptide antigen might influence its humoral 
immunogenicity, we chose to study the immune response 
to synthetic peptides representing an immunodominant CD4 
T  cell epitope of the bacteriophage X cI repressor.  A large 
fraction of the CD4 T cells that respond to the )x cI repressor 
in BALB/c and A/J mice are specific for the 12-26 region 
(18, 19) as defined by in vitro T cell activation assays using 
a synthetic peptide encompassing these residues. 
Materials and Methods 
Peptide Synthesis and Purification.  Peptides were synthesized as 
described (20) using a peptide synthesizer (430A; Applied Bin- 
systems, Inc., Foster City, CA), and purified  via either reverse-phase 
HPLC or a combination of HPLC and ion exchange chromatog- 
raphy. All peptides  were sequenced  using a protein sequencer (470A; 
Applied Biosystems, Inc.) before use. Proton-nuclear magnetic 
resonance (NMR) 1 spectra and amino acid compositions were ob- 
tained for selected peptides and demonstrated that they were >95% 
pure. 
Immunization of Mice and Assay of Hypersensitive Responses and 
Serum Antipeptide Antibody.  Lyophilized  peptides were dissolved 
in PBS at 2 rag/m1 and then emulsified in CFA at a ratio of one 
volume of adjuvant to one volume of peptide solution. Mice were 
immunized with 100 #1 of this emulsion intraperitoneally. Both 
IFA and Alum (a 9% solution mixed 1:1 with the antigen solution) 
were also used as adjuvants.  3 wk after immunization, 150-~d  blood 
samples were taken. 1 mo or more after priming, the mice were 
boosted with 100 ~g of peptide in either PBS, IFA, or Alum, 
intraperitoneally. The mice were then observed for at least 1 h to 
evaluate symptoms of  hypersensitivity  (see text). In peptide-mouse 
strain combinations that did not display hypersensitivity, symp- 
toms were not observed even if the boosting dose of peptide was 
raised to 200 ~g, or if mice were challenged multiple times at 2-wk 
intervals. Peptide-specific  IgE was assayed  using a rat passive cuta- 
neous anaphylaxis  (PCA) assay  (21). Halothane was used to anesthe- 
tize rats, rats were sensitized  with 100/~1 of  a 1:10 dilution of serum 
or greater injected intradermally on the back, rested for at least 
2 h, and challenged with 300/~g of peptide in 300/~1 of  PBS/0.5% 
Evans's blue injected  into the tail vein. r light chain-bearing  peptide- 
specific antibody was assayed  using a solid phase KIA (22). The 
heavy chain isotypes of serum antibodies specific for each peptide 
were also evaluated  using a solid phase KIA (22). A set of affinity- 
matched antiarsonate mAbs representing the different isotypes (see 
reference 22 for details) were used as controls. The values of serum 
dilutions that gave half-maximal  binding to the peptide-BSA  plates 
were then used to calculate the isotype values cited in the text, 
after correction for the different binding capacities and avidities 
1  Abbreviations  used in this  ~per: LN, lymph  node; NMR nuclear  magnetic 
resonance; PCA, passive cutaneous anaphylaxis. 
of the rabbit antiisotype sera. Peptides were covalently  crosslinked 
to BSA using carbodiimide as described (23). Histological exami- 
nations were performed on formalin-fixed  tissues by Anmed Bin- 
safe (Rockville, MD). 
T Cell Proliferation Assays.  Groups of at least four A/J mice 
were immunized in both hind footpads and at the base of the tail 
with 100/~g of each peptide emulsified in CFA. 1 wk later, in- 
guinal, popliteal, and para-aortic lymph nodes (LN) were taken, 
and pooled single  cell suspensions  were generated. 100-/~1 microcul- 
tures were created using 5 x  10  s LN cells and either different  con- 
centrations of the peptide used for immunization or no additive. 
Cultures  were incubated for 2 d at 37~  and then 1 /~Ci of 
[3H]thymidine (35 Ci/mmol) was added. The cultures were in- 
cubated for at least a further 6 h, and the cells harvested on glass 
fiber falters. The filters were dried, and incorporated 3H measured 
by scintillation counting. 
Generation of T Celt Hybridomas and Cytokine Assays.  Groups 
of four A/J mice were immunized with 100/~g of peptide, and 
either 7 or 30 d later, spleens were taken, single cell suspensions 
prepared, stimulated with 10/~g/ml peptide in vitro, fused to 
BW5147cV/3- (24), and hybridomas selected, all as previously  de- 
scribed (19). The resulting hybridomas were then stimulated with 
10 #M of the immunizing peptide using the TA3 lymphoma as 
APC. After 1 d, supernatants  were harvested  and Ib2 and I1`4 were 
assayed using the CTLL.2 and CT.4S (25) indicator lines, respec- 
tively. The 11Bll anti-I1`4 mAb (26) was included in CTLL.2 cul- 
tures to prevent overlap stimulation by Ib4. A cytokine response 
to peptide judged to be significant gave indicator line proliferation 
of at least 10-fold above controls lacking peptide. Such a response 
corresponded to that induced by 0.5 U/ml of  recombinant cytokine 
(Genzyme, Boston, MA). The CTLL response to 1I,2 was reduced 
by 15% when grown in media-containing 10% (volume basis) of 
11Bll hybridoma supernatant. An I1.,4 response under such condi- 
tions was undetectable. 
Results 
Synthetic Peptides Representing the Immunodominant CD4 Y 
Cell Epitope of the Bacteriophage )~ cI Repressor Protein Induce 
Immediate-type Hypersensitivity in Mice.  Previous experiments 
have shown that a linear synthetic peptide encompassing the 
12-26 region ofcI repressor can prime a CD4 T cell response 
and elicit a serum antibody response  in BALB/c mice (27). 
In these previous experiments,  12-26 was administered in 
Freund's adjuvant to elicit both primary (CFA) and secondary 
(IFA) responses.  However, when BALB/c mice were given 
a secondary intraperitoneal challenge of 100/~g of 12-26 in 
saline 1 mo after a primary intraperitoneal injection of 100 
/~g of 12-26 in CFA, a major fraction of the mice died within 
1 h. Death was preceded by a cumulative progression of the 
following symptoms: reddening of the ears, tail, and footpads; 
lack of movement upon prompting; and shallow breathing 
and prostrate posture. Necropsy revealed severe reddening of 
the intestines and lungs. Mice that did not die displayed many 
of these symptoms before an apparent complete recovery '~2 h 
after injection. The nature of these symptoms as well as their 
kinetics suggested systemic anaphylaxis, a diagnosis that was 
supported by histopathology of tissue sections obtained from 
the lungs, heart, and liver, which revealed extensive vascular 
congestion. 
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lenge was dependent on both the primary and secondary dose 
of peptide, as well as the method of administration.  50/~g 
of peptide was the smallest amount that could be given ei- 
ther at primary or secondary injection if reproducible symp- 
toms were to be observed. Primary immunization with pep- 
tide in saline  or IFA did not result in  sensitization,  while 
the use of Alum yielded a very low level of hypersensitivity. 
Secondary challenge with peptide in  IFA or on Alum did 
not result in a hypersensitive reaction.  Secondary challenge 
could be given either intraperitoneally or intravenously, with 
intravenous injection resulting in a slightly more rapid de- 
velopment of symptoms. Secondary injection in the footpad 
led to rapid local swelling that  was often followed by sys- 
temic anaphylaxis. 
To rule out the possibility that contaminants in the 12-26 
peptide preparation,  or in preparations  of peptides used in 
subsequent analyses,  could be responsible for the induction 
of hypersensitivity, three approaches were taken: (a) two in- 
dependent preparations  of each peptide were used in most 
cases and yielded similar results; (b) amino acid sequencing, 
amino acid composition, and proton NMR analyses were done 
on many of the purified peptide preparations  and revealed 
all to be >95% pure; and (c) a peptide with the same amino 
acid composition as a variant  12-26 peptide (12-26F22Y27; 
see below) but of a "random" sequence was used for immu- 
nization and found to fail to induce hypersensitivity. Collec- 
tively, these investigations revealed that the induction of hyper- 
sensitivity is not due to contaminants  that  co-purify with 
the peptides. 
12.26-based Peptide Induction of Hyp  ersensitivit~ Is MHC Re- 
stricted and CD4  T  Cell Dependent.  Further investigations 
of this  phenomenon  showed  that  it  was  not  confined  to 
BALB/c mice and the 12-26 peptide, but could be observed 
in a variety of different strains  of mice using either  12-26 
or amino acid variants of 12-26. Table 1 summarizes  these 
results. The induction of hypersensitivity is CD4 T cell de- 
pendent,  since hypersensitivity is induced by 12-26F22Y27 
in BALB/c mice but not in athymic BALB/c nu/nu mice, and 
treatment of A/J mice with a mAb (GK1.5) specific for the 
CD4 cell surface antigen (28) before and during the primary 
anti-12-26F22Y27 response protects them from a hypersen- 
sitivity reaction upon secondary challenge.  While most of 
the 12-26-based peptides induced hypersensitivity in BALB/c 
and C.Ab20 mice (a BALB/c-derived congenic line that bears 
the IgH1  a locus), several peptides failed to induce hypersen- 
sitivity in A/J mice. 
Use of other inbred  strains  and strain  A  congenic mice 
differing only in subregions of the MHC revealed that  the 
induction  of hypersensitivity by the  12-26F22Y27 peptide 
is MHC restricted, requiring  the presence of class II MHC 
alleles (I-A  d or I-E  k) previously shown to encode restricting 
elements for the 12-26 region ofcI repressor (18, 29). In Table 
2, such alleles are underlined. The severity of hypersensitivity 
reactions  seems to be affected by factors other  than  MHC 
antigens, however. Strains that bore the b alleles of I-A and 
I-E did not develop hypersensitivity, consistent with previous 
observations that H2  b mice are T cell nonresponders to the 
12-26  region of cI repressor (27).  Taken  together with the 
data presented in Table 2, the data shown in Table 1 indicate 
Table  1.  Hypersensitivity  Responses to Various Peptides by Mice of Different Inbred Strains 
Hypersensitive  Response 
Peptide  Sequence  A/J  BALB/c  C.AL-20 
cI Repressor 
12-26 
12-26F22Y27 
12-26F22 
12-26Y27 
12-26F27 
12-24F22 
12-26C11F22Y27 
9-29 
9-29Ac 
Random  12-26F22Y27 
....  QEQLEDARRLKA  I YEKKKNEL  .... 
...............  No  Yes  Yes 
..........  F  ....  Y  Yes  Yes  Yes 
..........  F  ....  No  Yes  Yes 
...............  Y  No  No  No 
...............  F  Yes  Yes  Yes 
..........  F  -  -  No  Yes  ND 
C  ..........  F  ....  Y  Yes  ND  ND 
.....................  Yes  Yes  ND 
A c  .....................  Yes  ND  Yes 
DI  LKYKRKAFEKLEAR  No  ND  ND 
Shown are the name designation of each peptide,  its amino acid sequence as compared to the cI repressor using the one-letter code, and whether 
the peptide induces hypersensitivity in three strains of mice. Dashes indicate sequence identity. Differences are shown explicitly. C.AL-20 is a congenic 
strain bearing the IgH locus of A.LN (IgH1 d) on a BALB/c background. The 9-29Ac peptide has an acetylated NH2 terminus. In most cases, the 
data represent  the sum of two independent experiments  using different preparations  of each peptide. 
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H2 
Hypersensitive response 
Strain  K  I-A  I-E  S  D  to 12-26F22Y27 
Inbred 
MHC congenic 
A/J  k  k  k  d  d  +  +  + 
C3H  k  k  k  k  k  + " 
CBA/J  k  k  k  k  k  +  + 
CBA/NJ  k  k  k  k  k  +  + + + 
BALB/c  d  d  d  d  d  +  + 
C.AL-20  d  d  d  d  d  +  +  +  + 
C57BL/6  b  b  b  b  b  - 
C57BL/10  b  b  b  b  b  - 
CAF1  k/d  k/d  k/d  d  d  +  + + 
A/WySn  k  k  k  d  d  +  + 
A.TL/SfDuEg  s  k  k  k  d  +  + + 
A.TBK1  s  k  k  k  b  + * 
A.TBK16  s  k  k  k  b  +  +  + 
A.TBK2  s  k  b  b  b  - 
A.TBK3  s  k  b  b  b  - 
A.TH/SfDuEg  s  s  s  s  d  - 
A.BTK4  b  b  b  b  d  - 
A.BY/Sn  b  b  b  b  b  - 
A.CA/Sn  f  f  f  f  f  - 
B10.A  k  k  k  d  d  + 
At least five mice of each strain were immunized and challenged with the 12-26F22Y27 peptide and evaluated for hypersensitivity as described in 
Materials and Methods. The MHC alleles present in each strain are indicated (H2). Class II MHC alleles (I-A and I-E) previously shown to encode 
restricting elements for the 12-26 region ofcI repressor (18, 29) are underlined. Hypersensitivity  reactions were rank ordered as follows: +, reddening 
of the feet, tail, and ears within 10 min of challenge; + +, visible behavior modification within 15 min of challenge (usually manifest as infrequent 
movement); + + +, lack of movement upon prompting within 30 min of challenge (prostrate posture); + + + +, death within 2 h after challenge. 
For each condition, the "scores" of individual mice were averaged. In the case of some strains of mice, only mild symptoms or no symptoms were 
observed after initial boosting. In these cases, mice were challenged again 2 wk after the initial challenge and re-evaluated for symptoms. Mice that 
did not display hypersensitivity did not do so even after two challenges of 200/~g of peptide spaced at 2-wk intervals. The origin and characteristics 
of the A.TBK and A.BTK MHC recombinant strains can be found in references 64 and 65. The data from the congenic mice suggest that the 
hypersensitive response to 12-26F22Y27 can be I-E  k restricted. In addition, since the s, b, and f haplotypes do not encode a functional I-E molecule 
(64), the combined data in this table do not rule out the possibility that a hypersensitive response to 12-26F22Y27 requires the I-E molecule in 
other haplotypes. 
* Slightly less than one '+'. 
that  the  H2  d haplotype is  more "permissive"  than  H2  k in 
allowing induction  of hypersensitivity  to variant  forms of 
the  12-26 peptide. 
Quantitative Differences in the CD4 T Cell Response to Different 
Peptides.  The results presented above suggest that only cer- 
tain peptide-dass II antigen combinations induce the devel- 
opment of a hypersensitive response.  These data also show 
that  the presence of an appropriate class II-restricting ele- 
ment(s) for the 12-26 region is not sufficient to allow induc- 
tion of hypersensitivity by all of the  12-26-based peptides. 
Before this  study,  CD4 T  cell responsiveness  to 12-26 and 
several  of the sequence variants used here had been defined 
by ability  to induce T  cell activation in vitro using either 
T  cells  that had been primed in vivo using the 1-102 frag- 
ment ofcI repressor,  or T cell hybridomas that had been elicited 
using this  same antigen.  In addition,  the immunogenicity 
of several  of the variant forms of 12-26 (e.g.,  12-26F22Y27) 
had not been tested in these assays. Therefore, it was possible 
that mice that did not develop hypersensitivity after immu- 
nization with a given 12-26-based peptide might simply be 
incapable of mounting a CD4 T cell response to that peptide 
(i.e.,  were nonresponders). To test this idea, bulk LN T  cell 
stimulation assays were performed. As shown in Fig. 1, these 
analyses revealed that  some of the peptide-strain  combina- 
tions that did not show evidence of hypersensitivity gave rise 
to T  cell proliferative  responses  (e.g.,  12-26F22  and A/J). 
Therefore, mice can be T cell responders to a peptide without 
developing hypersensitivity to that peptide. Moreover, a com- 
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Figure 1.  Bulk T cell responses of lymph node cells from inbred  and 
MHC congenic mice to the peptide 12-26 and  12-26 sequence variants. 
Bulk LN proliferation assays were conducted as described in Materials and 
Methods.  The data presented represent an average of data from three inde- 
pendent  cultures  per point.  Error bars indicating SDs are shown.  The 
proliferative responses obtained  with A/J, BALB/c, and A strain  MHC 
congenic mice are shown in separate panels. In the case of A/J anti-12-26 
and  anti-12-26F22Y27  responses,  supernatants  were harvested  2 d after 
initiation of culture and assayed for the presence oflb2 using the CTLL.2 
indicator  line. In both cases, the amount of ID2 in the cultures correlated 
with the level of proliferation  as measured  by [3H]thymidine  incorpo- 
ration. 
parison of the data presented in Tables 1 and 2 and Fig.  1 
reveals that the magnitude of the in vitro T cell response to 
a given peptide is not indicative of its ability to induce hyper- 
sensitivity in viva. 
Analysis of Antibody Responses to the 12.26-based Peptides. 
The antibody isotype involved in immediate-type hypersen- 
sitivity (allergy, anaphylaxis) in humans is IgE (30). In mice, 
either IgE or IgG1 may be involved (30). Table 3 shows that 
peptide-specific  antibody of both these isotypes can be de- 
tected in primary immune sera of many mice that are hyper- 
sensitized.  Further, neither the IgG1 or IgE isotypes appear 
at significant  levels until ~2 wk after  primary immuniza- 
tion (data not shown). These kinetics correlate with the ki- 
netics of sensitization of the mice; a boosting injection of 
peptide before 3 wk after primary immunization fails to elicit 
a hypersensitivity reaction. 
Peptide-specific IgE cannot always be detected in primary 
sera of mice that are hypersensitized, and when such anti- 
body is detected, its estimated levels are low (50-500 ng/ml). 
If IgE is indeed the isotype responsible for the establishment 
of the hypersensitivity observed, our inability to detect pep- 
tide-specific antibody of this isotypic class in some of the 
hypersensitized mice may be due to  several factors.  First, 
peptide-specific IgE is not detected in mice that will become 
hypersensitized until "~14 d after primary immunization and 
declines  thereafter (data  not shown). Since primary bleeds 
on most mice were done at 21 d, the "peak" serum IgE level 
may well have been missed in many cases. Second, the sensi- 
tivity of the passive cutaneous anaphylaxis  IgE assay, in our 
hands, is "~50 ng/ml of antigen-specific  IgE. In some cases, 
this may not be adequate to allow detection ofpeptide-specific 
IgE levels that are sufficient  to sensitize  mice. Finally,  the 
IgE relevant to the state of hypersensitivity is presumably that 
bound to mast cells and basophils and not that found in the 
circulation. 
Nevertheless,  a correlation between the presence of pep- 
tide-specific serum IgE and the state of hypersensitivity is 
equivocal. Further, IgG1 is the predominant peptide-specific 
isotype present in all mice that are hypersensitized. Since this 
isotype has also been implicated in the development of im- 
mediate hypersensitivity in mice, it may be of central impor- 
tance in establishing the peptide-induced hypersensitivity de- 
scribed here. However, since peptide-specific  IgG1 is sometimes 
observed in the absence of hypersensitivity (see below), this 
conclusion remains tentative. 
The Role of lnterleukin 4 in the Development of  Peptide-induced 
Hypersensitivity.  It has been previously shown that the CD4 
T cell-derived cytokine IL-4 is necessary for the production 
of IgE during polyclonal B cell responses in vitro (31) and 
in viva (32). This cytokine also promotes the expression of 
the IgG1 isotype in vitro (33-35).  The isotypic profile  of 
antipeptide antibody in sera of hypersensitized mice suggests 
that IL-4 is involved in the regulation of isotype switching 
within the B cell population responding to peptide immuni- 
zation. Table 4 shows that treatment of A/J mice with the 
anti-IL-4  mAb  11Bll  (26)  during  the  primary  anti-12- 
26F22Y27 response dramatically reduced the number of mice 
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Peptide-specific antibody 
Percent of total isotypes 
Hypersensitive 
Peptide  Strain  Response  K  IgE  IgM  IgG1  IgG2  IgG3 
12-26  C.AL-20  Yes  120  + 
BALB/c  Yes  58  -  100  91 
A/J  No  35  - 
12-26F22  C.AL-20  Yes  1,300  +  3  97 
CAF1  Yes  810  - 
A/J  No  45  - 
12-26F27  CAF1  Yes  1,600  +  2  97  1 
A/J  Yes  280  + 
12-26Y27  C.AL-20  No  140  - 
A/J  No  37  - 
BALB/c  No  30  - 
12-26F22Y27  CAF1  Yes  1,100  16  84  0 
C.AL-20  Yes  820  + 
A/J  Yes  580  +  3  93  4 
A.TBR16  Yes  250  -  25  75  0 
A.TL  Yes  230  -  44  56 
A.TBR1  Yes  180  -  28  72  0 
A.CA/Sn  No  92  -  21  3  73 
B10.A  Yes  80  -  10  90 
A.BY/Sn  No  37  - 
A.TBR2  No  20  -  100  0 
A.TH  No  <20  - 
A/J  (anti-CD4)  No  <20  - 
BALB/c nu/nu  No  22 
Different strains of mice were immunized, bled at 21 d, and challenged with the indicated peptides, as described in Materials and Methods. When 
assays of the following types were not performed, this is indicated by a blank. The "K" values represent the serum dilution factor necessary to reduce 
binding of serum antipeptide antibodies bearing g light chains to a peptide-BSA conjugate to one-half saturation (22). The "IgE" values represent 
whether  or not a PCA reaction was obtained with a 1:10 dilution of serum or greater (none of the samples gave reproducible PCA reactions at 
a >1:100 dilution,  which corresponded to ~50 ng/ml of an antiarsonate IgE mAb that was used as a positive control).  The heavy chain isotype 
values represent the relative serum dilution factors necessary to reduce the binding of a given heavy chain isotype to a peptide-BSA conjugate to 
one-half saturation (22). These values are presented as the fraction of specific  isotype measured as compared to a sum of the dilution factors giving 
half saturation obtained for all the measured isotypes. In cases where only a subset of the isotypes were measured, the isotypes that were not measured 
are indicated by a blank. Also shown are the results of assays done on mice treated with the anti-CD4 mAb GK1.5 and BALB/c nude mice that 
had been immunized with 12-26F22Y27 (see text). 
showing symptoms of hypersensitivity upon secondary chal- 
lenge. Moreover, antipeptide antibody of the IgE isotype could 
not be detected in the sera of such mice, while the average 
levels of both  K light chain-bearing and IgG1 anti-peptide 
antibody were only slightly diminished as comparable to con- 
trols. In addition, in several of the 11Bll-treated mice that 
did not  show  symptoms  of hypersensitivity, the  levels of 
peptide-specific IgG1 were higher than in the untreated con- 
trois (data not shown). These data are in accord with those 
of others showing that in vivo IgE responses are much more 
susceptible than are IgG1 responses to inhibition by anti-IL4 
(32),  and also indicate that IgE may be of primary impor- 
tance in the establishment of peptide-induced hypersensitivity 
in this case. 
The IL-4 dependence of hypersensitivity and the lack of 
correlation between  a  peptide's ability to  induce  a  T  cell 
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Peptide-specific antibody 
Percent  of total isotypes 
Mice displaying symptoms 
Condition  of hypersensitivity  r  IgE  IgM  IgG3  IgG1  IgG2a  IgG2b 
12-26F22Y27  7/8  160  +  0  1  85  4  10 
12-26F22Y27 and 
a-IL-4 (11Bll)  2/8  98  -  0  1  63  12  24 
Two groups of eight A/J mice each were primed with the 12-26F22Y27  peptide  in CFA as described  in Materials  and Methods. One group was 
injected intraperitoneally  at 2-3-d intervals with 0.5 ml of ascites fluid containing m500 #g of the anti-IL-4  mAb 11Bli (26),  starting 1 wk before 
immunization.  The 11Bll injections  were continued until 1 mo after  immunization. 3 wk after  immunization, blood samples were taken  from 
the mice, samples from the same group were pooled, and assayed for the presence of peptide-specific IgE and other isotypes as described in Materials 
and Methods. I mo after immunizaiton, both groups of mice were challenged with 12-26F22Y27 in PBS, and symptoms of hypersensitivity  evaluated 
as described  in the text and in the legend to Table 2.  The levels of total antipeptide  antibody bearing r  light chain  and  of various  isotypes  were 
determined and  are indicated  as described  in Materials  and  Methods. 
proliferative response and its ability to induce hypersensitivity 
suggested that IL-4 expressing peptide-specific CD4 T  cells 
might be absent from mice that did not develop hypersensi- 
tivity but present in those that did. To investigate this issue, 
T  cell hybridomas were generated from A/J mice either 7 
or 30 d after immunization with 12-26F22Y27,  which in- 
duces hypersensitivity in this strain, and 30 d after immuni- 
zation with 12-26, which fails to induce hypersensitivity in 
A/J mice. The resulting hybridomas were then challenged 
in vitro with the immunizing peptide using a B lymphoma 
APC line, and IL-2 and I1.-4 production was assayed. Table 
5 shows that >50% of the hybridomas elicited at 30 d with 
12-26F22Y27  produce both I1.-2 and I1.-4 upon challenge, 
while only two of the hybridomas elicited at 30 d after im- 
munization with 12-26 produce ILo4 in addition to IL-2. The 
production of IL-2 by these hybridomas may not be an ac- 
curate indication of the status of IL-2 production by their 
T cell precursors, since the fusion partner used for construc- 
tion of these cell lines (BW5147) secretes  IIr  upon activa- 
tion (36). 
Interestingly, all of the 12-26F22Y27-induced hybridomas 
isolated at day 7 produce II.-2 in response to antigen chal- 
lenge, but none produce significant amounts of II:4.  The 
absence of IL-4-producing CD4 T cells early in immune re- 
sponses  has been observed by others (37-39),  and indicates 
that the IL-4 phenotype must be developed within the re- 
sponding CD4 T  population during the course of the pri- 
mary response. This early absence also correlates with the 
inability to induce a hypersensitive response 1 wk after im- 
munization of A/J mice with  12-26F22Y27. 
Lack of B Cell Epitopes Does Not Explain the Differential In- 
duction of Hypersensitivity by Different Peptides.  As shown in 
Table 3,  most peptide-strain combinations that do not dis- 
play hypersensitivity are also characterized by low peptide- 
specific serum antibody levels. Comparison of these data with 
those in Fig.  1 demonstrates that this lack of induction of 
hypersensitivity and poor humoral responsiveness does not 
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correlate with inability to induce a T  cell proliferative re- 
sponse.  However, this inability could result from the B cell 
compartment of a particular strain of mouse being inefficient 
at recognizing a given peptide. The data presented in Tables 
2 and 3 are rather uninformative in this regard, since the strain 
A congenics that do not develop hypersensitivity in response 
to immunization with 12-26F22Y27  express class II alleles 
that have previously been shown not to be good restricting 
elements for the 12-26 region ofcI repressor (27). Therefore, 
to further investigate this issue, BALB/c and its MHC con- 
genic strain counterpart BALB.K were used. Since both these 
Table  5.  IL-2 and IL.4 Production by T  Cell Hybridomas Made 
at 7 or 30 d after Immunization  of A/J Mice with 12-26 
or 12-26F22Y27 
Total no. of 
antigen-specific  IL-2  IL-2 and IL-4 
Condition  hybridomas  Producers  Producers 
12-26F22Y27,  37  37  0 
day 7 
12-26F22Y27,  72  35  37 
day 30 
12-26,  21  19  2 
day 30 
Experiments  were conducted as described in Materials and Methods. As- 
signments to the "IL-2 producers" or "IL-2 and IL-4 producers" categories 
were based on two independent  assays. In the case of the hybridomas 
that produced both IL-2 and IL-4 upon peptide stimulation,  dose-response 
titrations revealed that in all cases the dose of peptide required to give 
half-maximal IL-2 production was always less than that required to give 
half-maximal  IL-4 production. Interestingly, however, the ratio of these 
values varied  over a  100-fold range. 130 
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Figure 2.  Proliferative  responses to the peptides 12-26F22 and 12- 
26F22Y27 of LN cells  from  BALB/c and BALB.K  mice. LN T cell  prolifer- 
ation experiments  were conducted  as described  in Materials and Methods 
using lymph  nodes from  at least four mice  per condition.  Each data  point 
represents an average  of results from  four independent  cultures, and error 
bars indicating SDs are shown. 
strains of mice express class II alleles (I-A  d or I-E  k) previously 
shown to be restricting elements for the 12-26 region (18, 
29),  we anticipated that a T  cell immune response  would 
be induced by 12-26-based peptides in both strains of mice. 
Indeed, Fig. 2 shows that 12-26F22 and 12-26F22Y27  both 
elicited LN T  cell proliferative responses in both strains.  In 
addition,  12-26F22Y27  induced high levels of serum anti- 
body dominated by IgG1, as well as hypersensitivity in both 
these strains (Table 6). In marked contrast, 12-26F22 induced 
only very low levels of serum antibody in both strains,  and 
hypersensitivity only in BALB/c. Since these two strains differ 
only at the MHC, and, thus, should express identical anti- 
body V region repertoires, the differential induction of serum 
antibody responses and hypersensitivity by 12-26F22 cannot 
be due to differences in the ability of the B cell compartment 
of these two strains to recognize this peptide. These data fur- 
ther support the conclusion that the ability of a given pep- 
tide to induce a T cell proliferative response does not corre- 
late  with  its  ability  to  induce  antibody production  and 
hypersensitivity. 
Discussion 
Peptides representing an immunodominant CD4 T cell epi- 
tope of the bacteriophage X cI repressor  that differ subtly 
in primary structure induce immune responses in mice that 
differ both quantitatively and qualitatively. Peptides that in- 
duce hypersensitivity elicit IgG1, and many times IgE responses 
as well, but sometimes fail to elicit T  cell proliferative re- 
sponses. Peptides that do not induce hypersensitivity usually 
do not elicit good antibody responses  but can induce vig- 
orous T cell proliferative responses. Further, such differences 
can also be observed when a particular peptide is used to im- 
munize mice that differ only in MHC haplotype. 
Our results raise concerns about the general use of small 
synthetic peptides as human vaccines and therapeutic antag- 
onists of activation of certain subsets of T cells. Recent ex- 
periments have shown that ability to induce hypersensitivity 
is not idiosyncratic to 12-26 and its amino acid variants, a 
peptide representing amino acids  130-142  of the influenza 
hemagglutinin, can also elicit hypersensitivity in certain strains 
of mice when injected in CFA. Our finding that CFA is a 
better adjuvant than Alum for the induction of hypersensi- 
tivity by these peptides appears  to contrast with the work 
of others using high molecular weight protein antigens. Such 
antigens induce immunity when administered in CFA and 
elicit persistent IgE responses only when administered at low 
doses,  usually on Alum (40-42).  We are  unaware of any 
previous reports showing that levels of protein-Alum-induced 
serum  IgE  correlate  with  the  ability to  induce  systemic 
anaphylaxis in mice, however. In addition, the peptide-induced 
hypersensitivity described here is usually correlated with high 
levels of serum antipeptide IgG1 and low, transient levels of 
Table  6.  Peptide-specific  Antibody and Hypersensitive Responses in BALB/c and BALB.K Mice 
Peptide-specific antibody 
Percent of total isotypes 
Hypersensitive 
Strain  Peptide  Response  K  IgM  IgG1  IgG2a  IgG2b  IgG3 
BALB/c  12-26F22Y27  + + + +  1,000  0  91  5  4  0 
BALB.K  12-26F22Y27  + + + +  610  0  93  4  3  0 
BALB/c  12-26F22  + + +  36  0  79  11  10  0 
BALB.K  12-26F22  -  33  0  71  16  13  0 
At least four mice for each condition  were immunized,  bled, boosted, and evaluated  for symptoms  of systemic  anaphylaxis  as described in the legends 
to Tables 1 and 2. Peptide-specific  antibodies of the x and heavy  chain isotypic  classes were measured in pooled serum samples as described in the 
legend to Table 3 and Materials and Methods. The extremely  low levels of serum antibody  in mice immunized with 12-26F22 were not due to 
this response being dominated  by X light chain bearing antibodies, since reactivity of the anti-12-26F22 antibody present in sera from such mice 
is >10-fold lower than the anti-12-26F22Y27 antisera with the anti-IgG1 reagent. 
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is often observed in response to protein antigens administered 
in CFA (43, 44). Determining the immunological basis for 
the qualitative difference in outcome of immune responses 
to high molecular weight protein antigens versus the hyper- 
sensitivity-inducing peptides described here clearly requires 
further investigation. 
It is tempting to interpret our results within the context 
of those of others suggesting that at least two subsets of mouse 
CD4 T cells exist: Thl and Th2 (45). Cell lines representing 
these subsets differ both with respect to their requirements 
for activation (46, 47), and the cytokines they produce (45). 
Th2 cells produce Ib4, -5, and -6 upon activation and serve 
as efficient B cell helpers (48,  49).  Thl cells produce IL-2, 
IFN-% and TNF, and appear to be responsible for the induc- 
tion of cell-mediated immune responses such as delayed-type 
hypersensitivity (50,  51).  Our data are consistent with the 
notion that whether a T cell proliferative (Thl?) or B helper 
response (Th2?) is developed by the CD4 T  cell population 
depends on both the nature of the antigen and the MHC 
haplotype. Other investigators have noted a dichotomy be- 
tween the T cell proliferative responses and the response that 
generates T cells that can help B cells to secrete antigen-specific 
antibody in vitro based on peptide antigen or MHC differ- 
ences (52-54).  Further, Bottomly and colleagues (55) have 
shown that the CD4 T  cell response to type IV collagen is 
of a Thl type in A,SW mice but of a Th2 type in A.BY 
mice (55). The dichotomy we have observed between 12-26- 
based peptide-induced T cell proliferation and hypersensitivity, 
antibody, and Ib4 production may be reflective of a far greater 
diversity of CD4 T cell functionally induced by different pep- 
tide-class  II combinations. 
Three general models, which are not mutually exclusive, 
can be proposed to account for these results: (a) CD4 T cell 
subsets committed to different cytokine phenotypes express 
different antigen receptor repertoires; (b) The density of the 
class II-peptide ligand for the TCR on APCs either deter- 
mines the cytokine phenotype to which an activated CD4 
T  cell  will  differentiate,  or  determines  which  cytokine- 
committed CD4 T  subset will be activated; and (c) distinct 
APC are involved in the generation and/or presentation of 
different immunogenic peptides to CD4 T cells, and by virtue 
of their production of different "costimulatory" factors for 
CD4 T cells, either determine the cytokine phenotype to which 
an activated CD4 T cell will differentiate, or determine which 
phenotype-committed CD4 T  cell subset is activated. Sup- 
port for models b and c can be garnered from the literature. 
High levels of signalling through the TCR or CD3 complex 
inhibit the proliferation of Thl cells but not Th2 cells (56--58), 
these cell types appear to use different "second messenger" 
pathways  for  TCR  signal  transduction  (47,  59),  and  the 
production of particular cytokines by CD4 T  cells depends 
on the nature of the stimulatory signal used (60,  61),  sup- 
porting model b. Th2 cells require II:1 for initiation of auto- 
crine proliferation, while Thl cells do not (46,  62),  and B 
cells serve as better APC than adherent cells for Th2 cells, 
but not for Thl  cells (39,  47),  supporting model 3. 
In the case of the peptide-induced immune responses de- 
scribed here, the first model would require that the antigen 
receptor repertoires of different CD4 T cell subsets be capable 
of distinguishing peptides that differed by as little as a single 
amino acid residue (e.g., 12-26F22 vs. 12-26F22Y27). While 
this notion remains to be tested, it seems unlikely given the 
general diversity of specificities resident in the mouse oe/3 
TCR repertoire (63). The third model either requires a mech- 
anism that targets subtly different peptides to distinct APC, 
or a mechanism that results in differential stability of a par- 
ticular peptide in distinct APC. Since current knowledge of 
antigen trafficking and how the antigen processing machinery 
present in different types of APC might differ is limited, fur- 
ther speculation regarding this model must await further data. 
The second model is consistent with the present understanding 
ofpeptide-MHC interaction in that changes in the agretypic 
interactions of a peptide and class II MHC antigen could be 
translated into differences in the density of their complex on 
the surface of the APC. Such differences might be transduced 
into different levels of T cell cytokine production if the cytokine 
genes  required  different  levels  of  TCR  complex-derived 
"second messengers" for their expression. An evaluation of 
the validity of these models in the case of immune responses 
elicited by 12-26-based peptides is clearly required. This will 
necessitate characterization of the receptor repertoires, cytokine 
phenotypes, and in vitro APC preferences of CD4 T  cells 
elicited by 12-26 peptides that either do or do not elicit hu- 
moral responses and hypersensitivity, as well as measurement 
of the affinities of MHC class II molecules for such peptides. 
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